The ankle–brachial index (ABI) can be used to assess the risk of cardiovascular events. The AAA trial aimed to determine whether low-dose aspirin was of net benefit among apparently healthy people with an ABI ≤0.95. The largely negative findings of this study raise important mechanistic and practical questions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300, 197–208 (2008).
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).
Fowkes, F. G. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303, 841–848 (2010).
Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).
Berger, J. S., Krantz, M. J., Kittelson, J. M. & Hiatt, W. R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301, 1909–1919 (2009).
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J. & Roth, G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl. 3), 234S–264S (2004).
Cattaneo, M. New P2Y12 inhibitors. Circulation 121, 171–179 (2010).
Davì, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482–2494 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C. Patrono is a consultant for and is in the speaker's bureau of AstraZeneca, Bayer Schering Pharma, Eli Lilly, Schering-Plough and Servier, is a consultant for Sanofi-Aventis, and received financial research support from Bayer Schering Pharma and Servier. C. Baigent declares no competing interests.
Rights and permissions
About this article
Cite this article
Patrono, C., Baigent, C. Aspirin for asymptomatic atherosclerosis?. Nat Rev Cardiol 7, 306–307 (2010). https://doi.org/10.1038/nrcardio.2010.65
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.65
